CL2022002191A1 - Peptides and their combinations for use in immunotherapy against various types of cancer - Google Patents

Peptides and their combinations for use in immunotherapy against various types of cancer

Info

Publication number
CL2022002191A1
CL2022002191A1 CL2022002191A CL2022002191A CL2022002191A1 CL 2022002191 A1 CL2022002191 A1 CL 2022002191A1 CL 2022002191 A CL2022002191 A CL 2022002191A CL 2022002191 A CL2022002191 A CL 2022002191A CL 2022002191 A1 CL2022002191 A1 CL 2022002191A1
Authority
CL
Chile
Prior art keywords
peptides
relates
present
immunotherapy against
cancer
Prior art date
Application number
CL2022002191A
Other languages
Spanish (es)
Inventor
Di Marco Moreno
Haen Sebastian
Kowalewski Daniel
Löffler Markus
Nelde Annika
Rammensee Hans-Georg
Stevanovic Stefan
Trautwein Nico
Sarah Walz Juliane
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Priority to CL2022002191A priority Critical patent/CL2022002191A1/en
Publication of CL2022002191A1 publication Critical patent/CL2022002191A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos t asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos t que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (mhc), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos t solubles, y de otras moléculas de unión.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to immunotherapy against cancer. The present invention also relates to peptide epitopes for tumor-associated T-lymphocytes, alone or in combination with other tumor-associated peptides which, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex live T-lymphocytes that will then be transferred to patients. Peptides bound to major histocompatibility complex (mhc) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.

CL2022002191A 2022-08-12 2022-08-12 Peptides and their combinations for use in immunotherapy against various types of cancer CL2022002191A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CL2022002191A CL2022002191A1 (en) 2022-08-12 2022-08-12 Peptides and their combinations for use in immunotherapy against various types of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2022002191A CL2022002191A1 (en) 2022-08-12 2022-08-12 Peptides and their combinations for use in immunotherapy against various types of cancer

Publications (1)

Publication Number Publication Date
CL2022002191A1 true CL2022002191A1 (en) 2023-02-24

Family

ID=85799564

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002191A CL2022002191A1 (en) 2022-08-12 2022-08-12 Peptides and their combinations for use in immunotherapy against various types of cancer

Country Status (1)

Country Link
CL (1) CL2022002191A1 (en)

Similar Documents

Publication Publication Date Title
CL2023001346A1 (en) Use of peptides in immunotherapy against small cell lung cancer and others.
CO2018008763A2 (en) Peptides, combinations of peptides and cells for use in immunotherapy against urinary bladder cancer and other types of cancer
CL2020002123A1 (en) Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancer.
CL2022003406A1 (en) Peptides and their combinations for use in immunotherapy against ovarian cancer among others (divisional application of 201902093)
CO2019012077A2 (en) Peptides and combinations thereof for use in immunotherapy against various types of cancer
CO2021000534A2 (en) Immunotherapy with b * 07-restricted peptides and a combination of anticancer peptides and related methods
CO2021004270A2 (en) B * 44 Restricted Peptides for Use in Cancer Immunotherapy and Related Methods
CO2019012071A2 (en) Peptides and peptide combinations for use in immunotherapy against leukemia and other cancers
CO2021003404A2 (en) Immunotherapy with a * 01-restricted peptides and a combination of anticancer peptides and related methods
CO2020001141A2 (en) New peptides and new peptide combinations for use in immunotherapy against lung cancer, including nsclc, sclc, and other cancers
CL2022003381A1 (en) a*03-restricted peptides, use in cancer immunotherapy and related methods (split application 202003371)
CO2020013652A2 (en) Peptides for use in cancer immunotherapy
CL2021000177A1 (en) Peptides, peptide combinations, cells and kits for use in cancer immunotherapy (divisional application no. 201802360)
CL2021001336A1 (en) Immunotherapy with b * 08 restricted peptides and a combination of anticancer peptides and related methods
CO2022016247A2 (en) Peptides and peptide combinations for use in immunotherapy against haematological malignancies and other cancers
CL2021001525A1 (en) Novel peptides and novel peptide combinations as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer (divisional application no. 201803293)
CL2022002192A1 (en) Peptides and their combinations for use in immunotherapy against various types of cancer
CL2022002191A1 (en) Peptides and their combinations for use in immunotherapy against various types of cancer
CL2022001941A1 (en) Peptides and their combinations for use in immunotherapy against different types of cancer
AR114532A1 (en) PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCER
AR117437A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 08 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS
AR114736A1 (en) PEPTIDES RESTRICTED BY B * 44 FOR USE IN IMMUNOTHERAPY AGAINST CANCER AND RELATED METHODS
AR115881A1 (en) IMMUNOTHERAPY WITH PEPTIDES RESTRICTED TO B * 07 AND A COMBINATION OF PEPTIDES AGAINST CANCER AND RELATED METHODS
AR115254A1 (en) PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCER
AR110039A1 (en) PEPTIDES AND COMBINATION OF PEPTIDES AS A TARGET AND FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF BILIARY VESICLE AND COLANGIOCARCINOMA, AS WELL AS OTHER TYPES OF CANCER